

Review

Specification of arterial, venous, and lymphatic endothelial cells during embryonic development

Tsutomu Kume

Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, USA

Summary. The groundbreaking discovery about arterial and venous expression of ephrinB2 and EphB4, respectively, in early embryonic development has led to a new paradigm for vascular research, providing compelling evidence that arterial and venous endothelial cells are established by genetic mechanisms before circulation begins. For arterial specification, vascular endothelial growth factor (VEGF) induces expression of Notch signaling genes, including *Notch1* and its ligand, *Delta-like 4 (Dll4)*, and *Foxc1* and *Foxc2* transcription factors directly regulate *Dll4* expression. Upon activation of Notch signaling, the Notch downstream genes, *Hey1/2* in mice or *gridlock* in zebrafish, further promote arterial differentiation. On the other hand, the orphan nuclear receptor COUP-TFII is a determinant factor for venous specification by inhibiting expression of arterial specific genes, including *Nrp1* and *Notch*. After arterial and venous endothelial cells differentiate, a subpopulation of venous endothelial cells is thought to become competent to acquire lymphatic endothelial cell fate by progressively expressing the transcription factors *Sox18* and *Prox1* to differentiate into lymphatic endothelial cells. Therefore, it has now evident that arterial-venous cell fate determination and subsequent lymphatic development are regulated by the multi-step regulatory system associated with the key signaling pathways and transcription factors. Furthermore, new signaling molecules as additional regulators in these processes have recently been identified. As the mechanistic basis for a link between signaling pathways and transcriptional networks in arterial, venous and lymphatic endothelial cells begins to be uncovered, it is now time to summarize the literature on this exciting

topic and provide perspectives for future research in the field.

Key words: Arterial-venous specification, Lymphatic specification, VEGF, Notch, Fox

Introduction

During vascular development, angioblasts, which are multipotent endothelial progenitors originating from the mesoderm, coalesce and undergo vasculogenesis to form the primitive capillary plexus. Angiogenesis is the subsequent process of vascular remodeling and gives rise to a mature network of blood vessels including arteries and veins. This process is regulated in part by hemodynamic forces. However, recent studies in zebrafish and mice clearly demonstrate that in the developing embryo, arterial and venous identity is established by genetic mechanisms, including VEGF, Notch and ephrinB2, before circulation begins (Aitsebaomo et al., 2008; Hong et al., 2008; Swift and Weinstein, 2009). After arteriovenous diversification, a subpopulation of the venous cells acquires lymphatic cell fate by progressively expressing *Sox18* and *Prox1* and differentiates into lymphatic endothelial cells. This process leads to the formation of the second vascular network, the lymphatic vasculature. Despite recent advances toward understanding genetic programming in vascular development, there are many important questions that remain unanswered. In particular, the mechanisms underlying differential gene regulation and critical signaling pathways that are crucial for arterial, venous and lymphatic specification need to be determined. In this review, I will summarize the current understanding of endothelial cell specification during early embryonic development. A comprehensive summary of critical factors involved in arterial, venous

and lymphatic specification during vascular development is given in Table 1.

EphrinB2/EphB4

Given that arteries and veins are morphologically and physiologically distinct, it was, until recently, believed that they are formed from primitive blood vessels according to hemodynamic changes and physiological factors. However, seminal studies demonstrate that ephrinB2 and its receptor EphB4, members of the ephrin-Eph receptor tyrosine kinase family, are differentially expressed in arterial and venous endothelial cells of the early mouse embryo, respectively (Wang et al., 1998). Surprisingly, the expression of ephrinB2 and EphB4 is distinctively detected in the primary vascular plexus before the onset of circulation in the developing embryo. This provides the first evidence that arterial-venous identity is genetically predetermined, although several lines of evidence suggest there is local environments (e.g., hemodynamic forces) influences plasticity of arterial-venous identity (Moyon et al., 2001; Othman-Hassan et al., 2001; le Noble et al., 2004).

Consistent with the notion that ephrin-Eph signaling can be bidirectional, mice deficient for *ephrinB2* and *EphB4* have similar vascular defects in remodeling of primary capillary vessels into a mature vascular network composed of arteries and veins (Wang et al., 1998; Adams et al., 1999; Gerety et al., 1999; Gerety and Anderson, 2002). Importantly, these mutant mice do not have clear boundaries between arterial and venous vessels, indicating that ephrinB2-EphB4 signaling is required for the establishment and maintenance of arterial-venous interaction. However, the lack of *ephrinB2* or *EphB4* does not impair the specification of arteries and veins per se, and this observation led to the identification of other factors that act upstream of ephrinB2-EphB4 signaling in arterial-venous cell determination, as discussed below.

Arterial specification

Hedgehog

Sonic hedgehog (Shh) is a member of the Hedgehog family and is involved in numerous aspects of

Table 1. Factors involved in regulating arterial, venous, and lymphatic cell fates.

Factor	Phenotype/Role		References
Arterial identity	Shh	Loss of Shh results in lack of arterial identity in zebrafish. Shh acts upstream of VEGF	Lawson et al., 2002
	VEGF	VEGF acts downstream of Shh signaling to activate Notch via the PLC γ /ERK pathway in zebrafish. Mutant mice expressing only VEGF ₁₈₈ lack arterial differentiation	Lawson et al., 2002; Stalmans et al., 2002; Hong et al., 2006; Covassin et al., 2009
	Nrp1	Null mice display impaired arterial differentiation. Nrp1 is involved in a positive feedback loop of VEGF signaling	Mukouyama et al., 2005; Jones et al., 2008
	Notch	Notch acts downstream of Shh and VEGF signaling in zebrafish. Notch1; Notch4 mutant mice have abnormal vascular development.	Lawson et al., 2001, 2002; Krebs et al., 2000
	Dll4	Null mice lack arterial specification	Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004
	Dll1	Null mice fail to maintain arterial identity	Sorensen et al., 2009
	Hey1/2 (Gr1)	Null mice lack arterial specification. Lack of gr1 in zebrafish results in loss of arterial specification	Zhong et al., 2001; Fisher et al., 2004; Kokubo et al., 2005
	Foxc1/c2	Foxc1; Foxc2 mutant mice lack arterial specification. Foxc1 and Foxc2 directly regulate Dll4 and Hey2 expression. Foxc1 and Foxc2 are also involved in lymphatic vessel development.	Kume et al., 2001; Seo et al., 2006; Hayashi and Kume, 2008
	Sox7/18	Lack of Sox7/18 results in loss of arterial identity in zebrafish	Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008
	Snrk-1	Snrk-1 acts downstream or parallel to Notch signaling in zebrafish	Chun et al., 2009
	Dep1	Dep1 acts upstream of PI3K in arterial specification in zebrafish	Rodriguez et al., 2008
	Crlr	Shh regulates VEGF activity by controlling crlr expression in zebrafish	Nicoli et al., 2008
EphrinB2	Null mice lack boundaries between arteries and veins. EphrinB2 is involved in lymphatic vascular remodeling and maturation	Wang et al., 1998; Adams et al., 1999; Gerety and Anderson, 2002; Makinen et al., 2005	
Venous identity	COUP-TFII	COUP-TFII suppresses arterial cell fate by inhibiting Nrp1 and Notch. COUP-TFII also interacts with Prox1 to regulate lymphatic gene expression	You et al., 2005; Lee et al., 2009; Yamazaki et al., 2009
	EphB4	Null mice lack boundaries between arteries and veins	Gerety et al., 1999
Lymphatic identity	Sox18	Null mice fail to specify lymphatic endothelial cells. Sox18 induces Prox1 expression	Francois et al., 2008
	Prox1	Prox1 induces lymphatic markers and maintains lymphatic cell identity	Wigle and Oliver, 1999; Wigle et al., 2002; Hong et al., 2002; Petrova et al., 2002; Johnson et al., 2008

embryonic development. Shh acts as a secreted molecule and transmits its signal into recipient cells via the transmembrane receptor Patched (Ptc) and the G protein-coupled receptor Smoothed (Smo). Studies in the zebrafish have shown that Shh, secreted by the notochord at the midline of the developing embryo, induces arterial cell fate in angioblasts (Lawson et al., 2002). Zebrafish embryos lacking Shh signaling show loss of arterial expression of ephrinB2 and have a single axial vessel expressing venous markers, suggesting that Shh is required for arterial identity. On the other hand, exogenous expression of *Shh* in the zebrafish embryo induces ectopic formation of arterial endothelial cells expressing ephrinB2 within the trunk vessels. The effect of Shh on arterial identity in zebrafish is indirect by inducing expression of vascular endothelial growth factor (VEGF) in the adjacent somites. As described below, VEGF signaling acts downstream of Shh and in turn activates Notch signaling in endothelial cells to promote the arterial program (Lawson et al., 2001, 2002, 2003) (Fig. 1).

Although the role of Shh signaling in arterial specification has been well demonstrated in zebrafish, it is still unclear whether the mammalian homologues have similar functions during development. *Shh* mutant mice do not exhibit severe vascular defects, although they show reduced vascularization in the developing lung (van Tuyl et al., 2007). *Smo* mutant mice have defects in formation of the dorsal aorta and remodeling of the yolk sac vasculature (Byrd et al., 2002; Vokes et al., 2004). Although further examinations of the vascular phenotype in *Smo* mutants need to be performed, it is possible that murine Shh signaling is dispensable for arterial-venous specification.

VEGF

VEGF signaling is the best-known pathway that regulates the formation and morphogenesis of blood and lymphatic vessels in development and disease (Lohela et al., 2009). In zebrafish, loss of *VEGF* results in lack of arterial expression of ephrinB2, consistent with the observation that loss of Shh signaling leads to lack of VEGF expression in the somites. Importantly, overexpression of *VEGF* in the zebrafish embryo induces ectopic expression of arterial markers as seen in embryos overexpressing *Shh* and can rescue arterial expression in embryos lacking Shh signaling (Lawson et al., 2002). Zebrafish experiments including forward genetic screening have further revealed critical pathways mediated by VEGF in arterial cell fate determination. While the zebrafish VEGF receptor Kdr1 plays a major role in arterial development (Covassin et al., 2006, 2009), phospholipase C (PLC)- γ 1, an immediate downstream component of the VEGF receptors, is required for transducing VEGF signaling (Lawson et al., 2003; Covassin et al., 2009). Furthermore, phenotype-based small-molecule chemical screening on zebrafish *gridlock* mutant embryos described below have provided

evidence that a crosstalk between VEGF-activated intracellular signaling pathways, the phosphoinositide 3-kinase (PI3K) and the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathways, antagonistically regulate arterial-venous specification during development (Peterson et al., 2004; Hong et al., 2006, 2008).

Homozygous and heterozygous mutant mice for *VEGF* display embryonic lethality associated with cardiovascular defects, including abnormal blood vessel formation (Carmeliet et al., 1996; Ferrara et al., 1996). Interestingly, mutant mice expressing only the matrix-associated VEGF₁₈₈ isoform show impaired arterial differentiation in the retina, suggesting that the lower molecular weight isoforms (diffusible VEGF₁₂₀ and intermediate VEGF₁₆₆) are required for arterial development in the retina (Stalmans et al., 2002). Consistent with this finding, neuropilin-1 (Nrp1), a co-receptor for VEGF₁₆₄ to facilitate VEGF signaling in concert with VEGF receptor-2 (VEGFR2), is expressed in arterial endothelial cells (Herzog et al., 2001; Moyon et al., 2001; Mukoyama et al., 2002; le Noble et al., 2004). In fact, *Nrp1* mutant mouse embryos show impaired arterial differentiation, independent of blood flow patterns (Jones et al., 2008). Mukoyama et al. have also demonstrated that a critical step for arterial




Fig. 1. A model for molecular pathway for arterial, venous, and lymphatic cell fate determination in vertebrate embryo. The VEGF-VEGFR2/Nrp1 pathway activates Notch signaling in angioblasts, leading to the specification of arterial cell fate, while *crrl* controls VEGF expression. Dep1 acts upstream of the VEGF-activated PI3K pathway. Foxc1 and Foxc2 directly regulate Dll4 and Hey2 expression, presumably downstream of VEGF signaling. Sox7/18 and *snrk-1* may act upstream of *grl* (the Hey2 homologue in zebrafish). EphrinB2 is a downstream target of Notch. In venous endothelial progenitors, COUP-TFII suppresses Nrp1 and Notch activation and promotes venous cell fate. A subpopulation of venous endothelial cells subsequently expresses Sox18 and Prox1, thereby inducing lymphatic cell fate. COUP-TFII also contributes to lymphatic gene expression by interacting with Prox1.

differentiation is the induction of *Nrp1* expression by VEGF signaling as a positive feedback loop (Mukouyama et al., 2005). Thus, the VEGF-VEGFR2/*Nrp1* pathway is important for arterial specification during vascular development (Fig. 1).

Notch

The Notch signaling pathway directs cell fate decisions during embryonic development. Upon activation of a Notch receptor (Notch1 to -4 in mammals) by binding to one of ligands (Jagged-1 to -2 or Delta-like [Dll]1 to -3 in mammals), a proteolytic cleavage results in the release of the Notch intracellular domain (NICD) into the cytoplasm. The transcriptional regulator Suppressor of Hairless [Su(H)] then interacts with the translocated NICD in the nucleus, leading to the induction of the bHLH transcription factors, including *Hey1* and *Hey2* in mouse and *gridlock* (*grl*) in zebrafish. Notch receptors (Notch1 and Notch4 in mouse) and Notch ligands (Jagged1, Jagged2 and Dll4 in mouse) are specifically expressed in arterial endothelial cells of the early embryo. Importantly, studies in zebrafish have first provided compelling evidence that Notch signaling acts downstream of the Shh and VEGF pathways in arterial specification (Lawson et al., 2001, 2002).

Compound homozygous mutant mice for *Notch1* and *Notch4* exhibit abnormal vascular development (Krebs et al., 2000), whereas mice lacking *Dll4* show defects in arterial specification in a dosage dependent manner (Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004). While before embryonic day (E) 13.5, *Dll1* is not expressed in blood vessels of the developing mouse embryo, its expression is restricted to arterial endothelial cells beginning at E 13.5. Analysis of hypomorphic and endothelial-specific *Dll1* mutant mice reveals that *Dll1* is required for the maintenance of arterial identity (Sorensen et al., 2009). Interestingly, although these *Dll1* mutant mice display reduced expression of VEGFR2 and *Nrp1* and upregulation of the venous marker COUP-TFII, *Dll4* is still expressed in *Dll1*-mutant endothelial cells (Sorensen et al., 2009). These results suggest that *Dll4* is essential for initiating the arterial program, but is dispensable for maintaining arterial identity in the late stage of embryonic development. It is also worth noting that Notch signaling activated by *Dll1* regulates the *Nrp1* promoter, indicating direct control of VEGF responsiveness by Notch (Sorensen et al., 2009).

During vascular development, *Hey1/2* in mouse and *grl* in zebrafish act downstream of the Notch signaling pathway. Like *Dll4* mutant mice (Duarte et al., 2004), compound *Hey1* and *Hey2* mutant mice fail to express arterial markers such as ephrinB2 in endothelial cells and exhibit fusions between arteries and veins (arteriovenous malformations) (Fischer et al., 2004; Kokubo et al., 2005). *Grl* is a zebrafish ortholog of mammalian *Hey2* and is also involved in arterial specification in the zebrafish embryo (Zhong et al., 2001). Overexpression of *grl* results in suppression of

venous markers, but no ectopic expression of arterial markers. It is still unclear whether *grl* is a direct downstream target of Notch in zebrafish because *grl* expression is detected in zebrafish embryos defective of Notch signaling (Lawson et al., 2001). Consistently, it has been shown that *Hey2* expression is Notch-independent during cardiac development (Timmerman et al., 2004; Rutenberg et al., 2006).

Although critical signaling pathways including Shh, VEGF and Notch in arterial fate determination have now been identified, the regulatory mechanisms associated with the key signaling pathways and transcriptional networks need to be elucidated. As described below, recent evidence demonstrates that Fox and Sox transcription factors play major roles in arterial cell fate determination during embryonic development.

Foxc1 and Foxc2 transcription factors

Members of the Forkhead/Fox transcription factor family have been implicated in cardiovascular development and disease (Papanicolaou et al., 2008). In particular, two closely related proteins in the Foxc subfamily, *Foxc1* and *Foxc2*, play overlapping roles in cardiovascular development. Compound *Foxc1*; *Foxc2* homozygous mouse mutants show defective vascular remodeling of primitive blood vessels and abnormal vascular connections, arteriovenous malformations (Kume et al., 2001; Seo et al., 2006). It is important to note that arteriovenous malformations similarly develop in endothelial cells of mutant mice and zebrafish in which Notch signaling is defective (Lawson et al., 2001; Zhong et al., 2001; Duarte et al., 2004; Krebs et al., 2004; Kokubo et al., 2005). Endothelial cells of compound *Foxc1*; *Foxc2* homozygous mutants fail to express arterial-specific genes including *Dll4* and *Hey2*, whereas venous markers such as COUP-TFII and EphB4 are normally expressed in these mutant embryos (Seo et al., 2006). Most significantly, *Foxc1* and *Foxc2* can directly activate the *Dll4* promoter via a Foxc-binding element (FBE), suggesting that *Foxc1* and *Foxc2* act upstream of Notch signaling in arterial cell specification (Seo et al., 2006) (Fig. 1).

A recent study has further demonstrated that *Foxc1* and *Foxc2* directly regulate expression of the Notch target gene, *Hey2*, by activating its promoter in endothelial cells (Hayashi and Kume, 2008). The *Hey2* promoter includes two FBEs that are adjacent to a binding site for Su(H). Of significance is the finding that *Foxc2*, but not *Foxc1*, directly binds to Su(H) and forms a protein complex with Su(H) and NICD to induce the *Hey2* promoter. Thus, *Foxc2* functionally interacts with the Notch pathway to induce *Hey2* expression in endothelial cells (Hayashi and Kume, 2008).

Foxc-induced promoter activity of *Dll4* and *Hey2* is significantly enhanced by VEGF in endothelial cells (Hayashi and Kume, 2008). Consistent with the report that the VEGF-mediated PI3K pathway induces the transcription of *Notch1* and *Dll4* *in vitro* (Liu et al.,

2003), modulation of *Foxc* activity by VEGF is enhanced by the PI3K pathway or inhibited by the ERK/MAPK pathway. By contrast, in the zebrafish embryo, the VEGF-activated PI3K pathway inhibits the stimulation of the ERK signaling cascade, leading to the suppression of arterial differentiation (Hong et al., 2006). Although reasons for the discrepancy between the *in vitro* and *in vivo* results remain unclear, one possible explanation is that these *in vitro* experiments were not conducted in uncommitted endothelial progenitor cells (Liu et al., 2003; Hayashi and Kume, 2008). Alternatively, given evidence that endothelial cells have plasticity even after specification (Moyon et al., 2001; Othman-Hassan et al., 2001; le Noble et al., 2004), it is also possible that epigenetic regulation *in vivo* such as hemodynamic force and blood flow may affect genetic programming in arterial-venous specification of the developing embryo (Swift and Weinstein, 2009).

In *in vitro* differentiation of arterial and venous endothelial cells using mouse embryonic stem (ES) cells, high VEGF concentration (50 ng/ml) induces arterial marker genes, whereas low and intermediate VEGF concentrations (2 and 10 ng/ml, respectively) preferentially upregulate expression of the venous marker COUP-TFII (Lanner et al., 2007). This observation implies that graded VEGF signaling could govern preferential activation of either PI3K or ERK pathway. Since *Foxc1* and *Foxc2* are expressed in both arteries and veins in the mouse embryo (Seo et al., 2006), it is possible that VEGF-mediated posttranslational modifications, such as phosphorylation, are critical for the activation of *Foxc1* and *Foxc2* proteins in the induction of arterial-specific genes. Taken together, these findings suggest that *Foxc* transcriptional factors control multiple steps of the VEGF-Notch/Dll4-Hey2 molecular cascade, thereby promoting arterial cell determination.

Sox transcription factors

Three Sox genes, *Sox7*, *Sox17* and *Sox18*, encode proteins that belong to a subgroup (SoxF) of the Sox transcription factor family. All three genes are expressed in vascular endothelial cells during development, while only *Sox18* is expressed in lymphatic vessel development (Hosking et al., 2009). Consistent with their expression patterns, *Sox7* and *Sox18* have a cooperative role in the specification of arterial-venous identity in zebrafish development (Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008), whereas compound *Sox17*; *Sox18* mutant mice display defects in cardiovascular development and postnatal neovascularization (Matsui et al., 2006; Sakamoto et al., 2007). Although the mechanistic basis for the function of *Sox7/18* in arterial-venous specification remains unclear, it is noteworthy that the phenotypic similarities are observed between *Sox7/18*-deficient embryos and *grl* mutants and that *Sox7/18*-deficient embryos lack *grl*

expression. Thus, *Sox7* and *Sox18* may regulate arterial-venous specification, at least in part, by acting upstream of *grl*. As described below, *Sox18* also is an essential regulator of early lymphatic development. Recent studies demonstrate that *Sox7* and *Sox17*, as genetic modifiers, can be induced in lymphatic endothelial progenitors in the absence of *Sox18* in certain mouse strains and compensate the lymphatic phenotype of *Sox18* mutant mice (Hosking et al., 2009). Therefore, the three Sox transcription factors cooperatively act in multiple processes of endothelial specification during development (Fig. 1).

Novel signaling molecules in arterial specification

Sucrose nonfermenting-related kinase-1 (*snrk-1*), a relatively novel serine/threonine kinase that belongs to the class of AMP-activated protein kinases (AMPKs), has recently been implicated in arterial-venous specification in zebrafish (Chun et al., 2009). *Snrk-1* is specifically expressed in zebrafish vasculature and acts downstream or parallel to Notch signaling (Fig. 1). Importantly, *snrk-1* counteracts with the function of dual-specific phosphatase-5 (*dusp-5*) in vascular development, and mutations in human *snrk-1* and *dusp-5* are identified in venous or lymphatic malformation patients (Pramanik et al., 2009). As described below, lymphatic endothelial cells are derived from the venous lineage. Thus, protein phosphorylation/dephosphorylation mediated by *snrk-1* and *dusp-5* may be critical for the lineage determination of artery, vein, and lymphatic vessels.

Another phosphatase recently reported to be involved in arterial specification is the protein tyrosine phosphatase *Dep1*. Zebrafish *Dep1a* and *Dep1b* are both expressed in vascular endothelial cells, as well as in other embryonic tissues. Knockdown of both *Dep1a* and *Dep1b* in zebrafish results in reduced expression of arterial markers (*notch5*, *grl* and *ephrinB2*) and an expansion of venous markers (*epHB4* and *dab2*) in the vasculature (Rodriguez et al., 2008). By contrast, the PI3K inhibitor LY294002 as well as overexpression of NICD or *grl* can rescue the vascular phenotype of embryos with double knockdown of *Dep1a/Dep1b*. These findings suggest that *Dep1* is required for arterial-venous specification by acting upstream of the PI3K pathway (Fig. 1). Although *Dep1* has been shown to interact with VEGFR2-mediated signaling in endothelial cell-cell contacts (Grazia Lampugnani et al., 2003), further studies need to be performed to determine whether *Dep1* is directly associated with VEGFR2 signaling in the arterial program during development.

The calcitonin receptor-like receptor (*crlr*) is a 7-transmembrane G protein-coupled receptor and can function as a receptor for adrenomedullin. *Crlr* is expressed in the somite and arterial progenitors during zebrafish development. *Crlr*-deficient zebrafish embryos show loss of arterial gene expression such as *ephrinB2*

and *notch5* (Nicoli et al., 2008). While lack of *crlr* results in a reduction in *VEGF* expression in the somites, *VEGF* overexpression can rescue impaired arterial differentiation of *crlr*-deficient embryos (Nicoli et al., 2008), suggesting that *crlr* functions upstream of *VEGF* in arterial specification. On the other hand, *Shh* signaling regulates *crlr* expression in the somite. These results indicate that *Shh* modulates *VEGF* activity by controlling *crlr* expression in zebrafish. Consistent with the role of *crlr* in zebrafish embryos, analysis of the *in vitro* differentiation system of mouse ES cells has also revealed that adrenomedullin signaling coordinates with the *VEGF* and *Notch* pathways in arterial differentiation (Yurugi-Kobayashi et al., 2006).

Venous specification

According to a number of studies in the zebrafish embryo, it was thought that venous cell fate is a default status during early embryonic development and that the activation of *Notch* signaling mediated by the *Shh/VEGF* pathways augments arterial specification. However, You et al. have demonstrated that chicken ovalbumin upstream promoter-transcription factor (COUP-TFII), which is specifically expressed in venous endothelial cells, is a genetic determinant factor of venous specification by acting upstream of *EphB4* in mouse (You et al., 2005) (Fig. 1). COUP-TFII belongs to the orphan nuclear receptor family, although it has recently been shown to be a retinoic acid-activated receptor (Kruse et al., 2008). *COUP-TFII* mutant mice show ectopic expression of arterial markers such as *Nrp1*, *Notch1* and *eprnB2* in veins, while mis-expression of *COUP-TFII* in endothelial cells results in reduced expression of *Nrp1* and *Jagged1* in arteries (You et al., 2005). It should be noted that the lack of *COUP-TFII* leads to a slight reduction in *EphB4* expression in veins, suggesting that COUP-TFII is not a sole factors, but may cooperate with additional factor(s) in venous cell fate determination. Unlike arterial specification, the molecular mechanisms controlling venous specification remain largely unknown. Therefore, although COUP-TFII suppresses arterial cell fate by inhibiting expression of *Nrp1* and *Notch* (You et al., 2005), it is important to define the mechanistic basis for the action of COUP-TFII during arterial-venous specification. Significantly, after the process of the determination of arterial and venous cell fate, COUP-TFII is also critical for lymphatic gene expression by interacting with *Prox1* (see below). This observation supports evidence that the event of arterial-venous determination is progressively followed by lymphatic specification during embryonic development. Consistently, *Nrp2* is expressed in venous and lymphatic endothelial cells (Herzog et al., 2001; Yuan et al., 2002), while *VEGFR3* expression is initially detected in blood vessels of the early embryo, but becomes restricted to venous and then lymphatic endothelial cells at the late stages of development (Kaipainen et al., 1995; Kukk et al., 1996).

Lymphatic specification

The mammalian lymphatic vascular system originates solely from the venous endothelial cells (Srinivasan et al., 2007). After arterial and venous endothelial cells differentiate, a subpopulation of venous endothelial cells is thought to become competent to acquire lymphatic endothelial cell fate by progressively expressing the transcription factors *Sox18* and *Prox1* to differentiate into lymphatic endothelial cells (Adams and Alitalo, 2007; Kiefer and Adams, 2008; Maby-El Hajjami and Petrova, 2008). *VEGF-C*, a *VEGFR3* ligand, is expressed mainly in mesenchymal cells surrounding embryonic veins (Karkkainen et al., 2004). *Prox1/VEGFR3*-positive lymphatic endothelial progenitors subsequently bud and migrate from the veins via paracrine *VEGF-C/VEGFR3* signaling, leading to the formation of the lymphatic network, a process called (developmental) lymphangiogenesis (Adams and Alitalo, 2007; Kiefer and Adams, 2008; Maby-El Hajjami and Petrova, 2008).

Sox18 is first detected in a subpopulation of the cardinal vein and precedes the onset of *Prox1* expression. Although *Sox18* homozygous mutant mice on a mixed background do not have lymphatic defects because of genetic compensation by *Sox7* and *Sox17* (Hosking et al., 2009), these mutant embryos on a C57BL/6 genetic background show a complete blockade of lymphatic endothelial differentiation, accompanied by the lack of *Prox1* expression in the cardinal vein (Francois et al., 2008). Furthermore, *Sox18* can directly induce *Prox1* expression via two *Sox18*-binding sites on the *Prox1* promoter (Francois et al., 2008). These data indicate that *Sox18* directly acts upstream of *Prox1* in the specification of lymphatic cell fate during embryonic development (Fig. 1).

Compelling evidence shows that *Prox1* is a master regulator of lymphatic endothelial identity. *Prox1* mutant mice fail to specify lymphatic endothelial cells and lack the expression of lymphatic markers such as *VEGFR3* and *LYVE1* (Wigle and Oliver, 1999; Wigle et al., 2002). Indeed, endothelial cells sprouted from the cardinal vein of *Prox1*-deficient embryo express blood endothelial markers. These results demonstrate that the loss of *Prox1* in mouse results in an arrest of the lymphatic program. Consistent with the lymphatic phenotype in *Prox1* mutant mice, *Prox1* play a pivotal role in controlling lymphatic gene expression (Hong et al., 2002; Petrova et al., 2002). Recent studies further reinforce the importance of *Prox1* function in lymphatics (Johnson et al., 2008). *Prox1* suppresses blood endothelial cell identity and maintains lymphatic cell identity even in adult mice. Remarkably, analysis of inducible ablation of *Prox1* in mouse reveals that the loss of *Prox1* leads to reprogramming of the lymphatic cell phenotype to the blood endothelial cell phenotype. Together, these results clearly demonstrate that the two-endothelial identities are reversible depending on *Prox1* activity (Johnson et al., 2008), although it remains

unclear whether *Prox1*-deficient lymphatic endothelial cells can acquire venous or unspecified endothelial identity. It should be noted that *Sox18* seems essential for the induction of lymphatic differentiation, but dispensable for the maintenance of the lymphatic phenotype. Besides lymphatic endothelial identity, *Prox1* also controls the migration of lymphatic endothelial cells toward VEGF-C by directly inducing the expression of *FGFR3*, *VEGFR3* and *integrin $\alpha 9$* (Shin et al., 2006; Mishima et al., 2007).

Implications for regulators of arterial-venous identity in lymphatic vessel development

Since the lymphatic vasculature is derived from venous endothelial cells in mammals, it is, not surprisingly, important to state that several key factors involved in arterial-venous identity play important roles in lymphatic vessel development. For instance, *ephrinB2* plays a role in remodeling the lymphatic capillary plexus into a mature lymphatic network as well as lymphatic valve formation (Makinen et al., 2005). *Notch1* and *Notch4* have been shown to be expressed in normal and pathological lymphatics in mouse and human (Shawber et al., 2007). Given evidence that Notch signaling directly upregulates expression of *ephrinB2* and *VEGFR3* by activating their promoters in blood endothelial cells (Grego-Bessa et al., 2007; Shawber et al., 2007), it is plausible to consider the possibility that the Notch pathway may control *ephrinB2* and *VEGFR3* expression in lymphatic endothelial cells. Yet no lymphatic abnormalities have been reported on mutant mice for Notch signaling genes (Gridley, 2007), possibly because these Notch mutant mice die earlier than the onset of lymphatic vessel development.

The venous determinant factor COUP-TFII is reported to be expressed in lymphatic endothelial cells, and COUP-TFII and *Prox1* physically interact with each other (Lee et al., 2009; Yamazaki et al., 2009). COUP-TFII and *Prox1* cooperatively control lymphatic gene expression such as *VEGFR3* and *FGFR3* (Lee et al., 2009), supporting the idea that venous cell identity is a prerequisite for lymphatic specification. Interestingly, COUP-TFII negatively and positively regulates *VEGFR3* expression in blood and lymphatic endothelial cells, respectively (Yamazaki et al., 2009). COUP-TFII also suppresses *Prox1*-induced *cyclin E1* expression and cell proliferation (Yamazaki et al., 2009). Thus, it is likely that COUP-TFII differentially functions by interacting with other transcriptional regulators such as *Prox1* in venous and lymphatic endothelial cells.

Compound *Foxc1*^{+/-}; *Foxc2*^{-/-} mutant mice have a reduction in the number of *Prox1*⁺ lymphatic endothelial cells sprouting from the cardinal vein (Seo et al., 2006). Notably, while expression domains of *Foxc1* and *Foxc2* are overlapped with those of *VEGF-C* in the mesenchyme, compound *Foxc1*^{+/-}; *Foxc2*^{-/-} mutants exhibit significant reduction in *VEGF-C* expression. Therefore, *Foxc* transcription factors are likely to

regulate lymphatic vessel development in a paracrine manner. *Foxc2* homozygous mutant mice show defective lymphatic valve formation and abnormal pericyte recruitment of lymphatic vessels, and *Foxc2* and *VEGFR3* act through a common genetic pathway in lymphatic vessel development (Petrova et al., 2004). Recent evidence further demonstrates that during lymphatic valve formation, *Foxc2* interacts with another transcription factor, NFATc, which has previously been implicated in the formation of cardiac valves from the endocardium (Norrmen et al., 2009). These results provide evidence that like COUP-TFII, *Foxc2* is a critical regulator in multiple stages of vascular formation, including arterial specification and lymphatic vessel development.

Concluding remarks and future directions

Studies in zebrafish and mouse have made significant progress toward understanding arterial, venous, and lymphatic cell fate determination. For example, it has become evident that the developing embryo progressively acquires lymphatic specification after the arterial-venous fate decisions in vascular endothelial cells. Yet the mechanistic basis for a link between the key signaling pathways and transcriptional networks in the three similar, but distinct, endothelial cell populations is still not completely understood. Although the new molecules recently identified have been discussed in this review, additional factors and signaling pathways may need to be discovered to full understand the complex process of endothelial cell fate. In particular, the molecular hierarchies that act at the nexus of arterial, venous and lymphatic specification/differentiation remains to be elucidated. Addressing this fundamental question will lead to a more complete understanding of plasticity and/or reprogramming of one endothelial cell type to another and will also be clinically relevant to vascular disorders in humans.

Acknowledgements. This work was supported by a NIH grant (HL074121) to T.K.

References

- Adams R.H. and Alitalo K. (2007). Molecular regulation of angiogenesis and lymphangiogenesis. *Nat. Rev. Mol. Cell. Biol.* 8, 464-478.
- Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W., Deutsch U., Risau W. and Klein R. (1999). Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. *Genes Dev.* 13, 295-306.
- Aitsebarmo J., Portbury A.L., Schisler J.C. and Patterson C. (2008). Brothers and sisters: molecular insights into arterial-venous heterogeneity. *Circ. Res.* 103, 929-939.
- Byrd N., Becker S., Maye P., Narasimhaiah R., St-Jacques B., Zhang X., McMahon J., McMahon A. and Gabel L. (2002). Hedgehog is required for murine yolk sac angiogenesis. *Development* 129, 361-

- 372.
- Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoek A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W. and Nagy A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 380, 435-439.
- Cermenati S., Moleri S., Cimbri S., Corti P., Del Giacco L., Amodeo R., Dejana E., Koopman P., Cotelli F. and Beltrame M. (2008). Sox18 and Sox7 play redundant roles in vascular development. *Blood* 111, 2657-2666.
- Chun C.Z., Kaur S., Samant G.V., Wang L., Pramanik K., Garnaas M.K., Li K., Field L., Mukhopadhyay D. and Ramchandran R. (2009). Snrk-1 is involved in multiple steps of angioblast development and acts via notch signaling pathway in artery-vein specification in vertebrates. *Blood* 113, 1192-1199.
- Covassin L.D., Villefranc J.A., Kacergis M.C., Weinstein B.M. and Lawson N.D. (2006). Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. *Proc. Natl. Acad. Sci. USA* 103, 6554-6559.
- Covassin L.D., Siekmann A.F., Kacergis M.C., Laver E., Moore J.C., Villefranc J.A., Weinstein B.M. and Lawson N.D. (2009). A genetic screen for vascular mutants in zebrafish reveals dynamic roles for Vegf/Plcg1 signaling during artery development. *Dev. Biol.* 329, 212-226.
- Duarte A., Hirashima M., Benedito R., Trindade A., Diniz P., Bekman E., Costa L., Henrique D. and Rossant J. (2004). Dosage-sensitive requirement for mouse Dll4 in artery development. *Genes Dev.* 18, 2474-2478.
- Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J. and Moore M.W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* 380, 439-442.
- Fischer A., Schumacher N., Maier M., Sendtner M. and Gessler M. (2004). The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. *Genes Dev.* 18, 901-911.
- Francois M., Caprini A., Hosking B., Orsenigo F., Wilhelm D., Browne C., Paavonen K., Karnezis T., Shayan R., Downes M., Davidson T., Tutt D., Cheah K.S., Stacker S.A., Muscat G.E., Achen M.G., Dejana E. and Koopman P. (2008). Sox18 induces development of the lymphatic vasculature in mice. *Nature* 456, 643-647.
- Gale N.W., Dominguez M.G., Noguera I., Pan L., Hughes V., Valenzuela D.M., Murphy A.J., Adams N.C., Lin H.C., Holash J., Thurston G. and Yancopoulos G.D. (2004). Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. *Proc. Natl. Acad. Sci. USA* 101, 15949-15954.
- Gerety S.S. and Anderson D.J. (2002). Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. *Development* 129, 1397-1410.
- Gerety S.S., Wang H.U., Chen Z.F. and Anderson D.J. (1999). Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. *Mol. Cell* 4, 403-414.
- Grazia Lampugnani M., Zanetti A., Corada M., Takahashi T., Balconi G., Breviario F., Orsenigo F., Cattellino A., Kemler R., Daniel T.O. and Dejana E. (2003). Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. *J. Cell Biol.* 161, 793-804.
- Grego-Bessa J., Luna-Zurita L., del Monte G., Bolos V., Melgar P., Arandilla A., Garratt A.N., Zang H., Mukoyama Y.S., Chen H., Shou W., Ballestar E., Esteller M., Rojas A., Pérez-Pomares J.M. and de la Pompa J.L. (2007). Notch signaling is essential for ventricular chamber development. *Dev. Cell* 12, 415-429.
- Gridley T. (2007). Notch signaling in vascular development and physiology. *Development* 134, 2709-2718.
- Hayashi H. and Kume T. (2008). Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. *PLoS ONE* 3, e2401.
- Herpers R., van de Kamp E., Duckers H.J. and Schulte-Merker S. (2008). Redundant roles for sox7 and sox18 in arteriovenous specification in zebrafish. *Circ. Res.* 102, 12-15.
- Herzog Y., Kalcheim C., Kahane N., Reshef R. and Neufeld G. (2001). Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. *Mech. Dev.* 109, 115-119.
- Hong C.C., Peterson Q.P., Hong J.Y. and Peterson R.T. (2006). Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. *Curr. Biol.* 16, 1366-1372.
- Hong C.C., Kume T. and Peterson R.T. (2008). Role of crosstalk between phosphatidylinositol 3-kinase and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways in artery-vein specification. *Circ. Res.* 103, 573-579.
- Hong Y.K., Harvey N., Noh Y.H., Schacht V., Hirakawa S., Detmar M. and Oliver G. (2002). Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. *Dev. Dyn.* 225, 351-357.
- Hosking B., Francois M., Wilhelm D., Orsenigo F., Caprini A., Svingen T., Tutt D., Davidson T., Browne C., Dejana E. and Koopman P. (2009). Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice. *Development* 136, 2385-2391.
- Johnson N.C., Dillard M.E., Baluk P., McDonald D.M., Harvey N.L., Frase S.L. and Oliver G. (2008). Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. *Genes Dev.* 22, 3282-3291.
- Jones E.A., Yuan L., Breant C., Watts R.J. and Eichmann A. (2008). Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos. *Development* 135, 2479-2488.
- Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M. and Alitalo K. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proc. Natl. Acad. Sci. USA* 92, 3566-3570.
- Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., Talikka M., Rauvala H., Betsholtz C. and Alitalo K. (2004). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nat. Immunol.* 5, 74-80.
- Kiefer F. and Adams R.H. (2008). Lymphatic endothelial differentiation: start out with Sox--carry on with Prox. *Genome Biol.* 9, 243.
- Kokubo H., Miyagawa-Tomita S., Nakazawa M., Saga Y. and Johnson R.L. (2005). Mouse hesr1 and hesr2 genes are redundantly required to mediate Notch signaling in the developing cardiovascular system. *Dev. Biol.* 278, 301-309.
- Krebs L.T., Xue Y., Norton C.R., Shutter J.R., Maguire M., Sundberg J.P., Gallahan D., Closson V., Kitajewski J., Callahan R. Smith G.H., Stark K.L. and Gridley T. (2000). Notch signaling is essential for vascular morphogenesis in mice. *Genes Dev.* 14, 1343-1352.

Arterial, venous, and lymphatic endothelial identity

- Krebs L.T., Shutter J.R., Tanigaki K., Honjo T., Stark K.L. and Gridley T. (2004). Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. *Genes Dev.* 18, 2469-2473.
- Kruse S.W., Suino-Powell K., Zhou X.E., Kretschman J.E., Reynolds R., Vonnrhein C., Xu Y., Wang L., Tsai S.Y., Tsai M. J. and Xu H.E. (2008). Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. *PLoS Biol.* 6, e227.
- Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V. and Alitalo K. (1996). VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. *Development* 122, 3829-3837.
- Kume T., Jiang H., Topczewska J.M. and Hogan B.L. (2001). The murine winged helix transcription factors, *Foxc1* and *Foxc2*, are both required for cardiovascular development and somitogenesis. *Genes Dev.* 15, 2470-2482.
- Lanner F., Sohl M. and Farnebo F. (2007). Functional arterial and venous fate is determined by graded VEGF signaling and notch status during embryonic stem cell differentiation. *Arterioscler. Thromb. Vasc. Biol.* 27, 487-493.
- Lawson N.D., Scheer N., Pham V.N., Kim C.H., Chitnis A.B., Campos-Ortega J.A. and Weinstein B.M. (2001). Notch signaling is required for arterial-venous differentiation during embryonic vascular development. *Development* 128, 3675-3683.
- Lawson N.D., Vogel A.M. and Weinstein B.M. (2002). Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. *Dev. Cell* 3, 127-136.
- Lawson N.D., Mugford J.W., Diamond B.A. and Weinstein B.M. (2003). phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development. *Genes Dev.* 17, 1346-1351.
- le Noble F., Moyon D., Pardanaud L., Yuan L., Djonov V., Matthijsen R., Breant C., Fleury V. and Eichmann A. (2004). Flow regulates arterial-venous differentiation in the chick embryo yolk sac. *Development* 131, 361-375.
- Lee S., Kang J., Yoo J., Ganesan S.K., Cook S.C., Aguilar B., Ramu S., Lee J. and Hong Y.K. (2009). Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. *Blood* 113, 1856-1859.
- Liu Z.J., Shirakawa T., Li Y., Soma A., Oka M., Dotto G.P., Fairman R.M., Velazquez O.C. and Herlyn M. (2003). Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. *Mol. Cell Biol.* 23, 14-25.
- Lohela M., Bry M., Tammela T. and Alitalo K. (2009). VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. *Curr. Opin. Cell Biol.* 21, 154-165.
- Maby-El Hajjami H. and Petrova T.V. (2008). Developmental and pathological lymphangiogenesis: from models to human disease. *Histochem. Cell Biol.* 130, 1063-1078.
- Makinen T., Adams R.H., Bailey J., Lu Q., Ziemiecki A., Alitalo K., Klein R. and Wilkinson G.A. (2005). PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. *Genes Dev.* 19, 397-410.
- Matsui T., Kanai-Azuma M., Hara K., Matoba S., Hiramatsu R., Kawakami H., Kurohmaru M., Koopman P. and Kanai Y. (2006). Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. *J. Cell Sci.* 119, 3513-3526.
- Mishima K., Watabe T., Saito A., Yoshimatsu Y., Imaizumi N., Masui S., Hirashima M., Morisada T., Oike Y., Araie M., Niwa H., Kubo H., Suda T. and Miyazono K. (2007). Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. *Mol. Biol. Cell* 18, 1421-1429.
- Moyon D., Pardanaud L., Yuan L., Breant C. and Eichmann A. (2001). Plasticity of endothelial cells during arterial-venous differentiation in the avian embryo. *Development* 128, 3359-3370.
- Mukouyama Y.S., Shin D., Britsch S., Taniguchi M. and Anderson D.J. (2002). Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. *Cell* 109, 693-705.
- Mukouyama Y.S., Gerber H.P., Ferrara N., Gu C. and Anderson D.J. (2005). Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. *Development* 132, 941-952.
- Nicoli S., Tobia C., Gualandi L., De Sena G. and Presta M. (2008). Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. *Blood* 111, 4965-4972.
- Norrmann C., Ivanov K.I., Cheng J., Zangger N., Delorenzi M., Jaquet M., Miura N., Puolakkainen P., Horsley V., Hu J., Augustin H.G., Ylä-Herttuala S., Alitalo K. and Petrova T.V. (2009). FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. *J. Cell Biol.* 185, 439-457.
- Othman-Hassan K., Patel K., Papoutsis M., Rodriguez-Niedenfuhr M., Christ B. and Wilting J. (2001). Arterial identity of endothelial cells is controlled by local cues. *Dev. Biol.* 237, 398-409.
- Papanicolaou K.N., Izumiya Y. and Walsh K. (2008). Forkhead transcription factors and cardiovascular biology. *Circ. Res.* 102, 16-31.
- Pendeville H., Winandy M., Manfroid I., Nivelles O., Motte P., Pasque V., Peers B., Struman I., Martial J.A. and Voz M.L. (2008). Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. *Dev. Biol.* 317, 405-416.
- Peterson R.T., Shaw S.Y., Peterson T.A., Milan D.J., Zhong T.P., Schreiber S.L., MacRae C.A. and Fishman M.C. (2004). Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. *Nat. Biotechnol.* 22, 595-599.
- Petrova T.V., Makinen T., Makela T.P., Saarela J., Virtanen I., Ferrell R.E., Finegold D.N., Kerjaschki D., Ylä-Herttuala S. and Alitalo K. (2002). Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. *EMBO J.* 21, 4593-4599.
- Petrova T.V., Karpanen T., Norrmann C., Mellor R., Tamakoshi T., Finegold D., Ferrell R., Kerjaschki D., Mortimer P., Ylä-Herttuala S., Miura N. and Alitalo K. (2004). Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. *Nat. Med.* 10, 974-981.
- Pramanik K., Chun C.Z., Garnaas M.K., Samant G.V., Li K., Horswill M.A., North P.E. and Ramchandran R. (2009). Dusp-5 and Snrk-1 coordinately function during vascular development and disease. *Blood* 113, 1184-1191.
- Rodriguez F., Vacaru A., Overvoorde J. and den Hertog J. (2008). The receptor protein-tyrosine phosphatase, Dep1, acts in arterial/venous cell fate decisions in zebrafish development. *Dev. Biol.* 324, 122-130.
- Rutenberg J.B., Fischer A., Jia H., Gessler M., Zhong T.P. and Mercola M. (2006). Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. *Development*

- 133, 4381-4390.
- Sakamoto Y., Hara K., Kanai-Azuma M., Matsui T., Miura Y., Tsunekawa N., Kurohmaru M., Saijoh Y., Koopman P. and Kanai Y. (2007). Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos. *Biochem. Biophys. Res. Commun.* 360, 539-544.
- Seo S., Fujita H., Nakano A., Kang M., Duarte A. and Kume T. (2006). The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. *Dev. Biol.* 294, 458-470.
- Shawber C.J., Funahashi Y., Francisco E., Vorontchikhina M., Kitamura Y., Stowell S.A., Borisenko V., Feirt N., Podgrabinska S., Shiraishi K., Chawengsaksophak K., Rossant J., Accili D., Skobe M. and Kitajewski J. (2007). Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. *J. Clin. Invest.* 117, 3369-3382.
- Shin J.W., Min M., Larrieu-Lahargue F., Canron X., Kunstfeld R., Nguyen L., Henderson J.E., Bikfalvi A., Detmar M. and Hong Y.K. (2006). Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. *Mol. Biol. Cell.* 17, 576-584.
- Sorensen I., Adams R.H. and Gossler A. (2009). DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. *Blood* 113, 5680-5688.
- Srinivasan R.S., Dillard M.E., Lagutin O.V., Lin F.J., Tsai S., Tsai M.J., Samokhvalov I.M. and Oliver G. (2007). Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. *Genes Dev.* 21, 2422-2432.
- Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P. and D'Amore P.A. (2002). Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. *J. Clin. Invest.* 109, 327-336.
- Swift M.R. and Weinstein B.M. (2009). Arterial-venous specification during development. *Circ. Res.* 104, 576-588.
- Timmerman L.A., Grego-Bessa J., Raya A., Bertran E., Perez-Pomares J.M., Diez J., Aranda S., Palomo S., McCormick F., Izpisua-Belmonte J.C. and de la Pompa J.L. (2004). Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. *Genes Dev.* 18, 99-115.
- van Tuyl M., Groenman F., Wang J., Kuliszewski M., Liu J., Tibboel D. and Post M. (2007). Angiogenic factors stimulate tubular branching morphogenesis of sonic hedgehog-deficient lungs. *Dev. Biol.* 303, 514-526.
- Vokes S.A., Yatskevych T.A., Heimark R.L., McMahon J., McMahon A.P., Antin P.B. and Krieg P.A. (2004). Hedgehog signaling is essential for endothelial tube formation during vasculogenesis. *Development* 131, 4371-4380.
- Wang H.U., Chen Z.F. and Anderson D.J. (1998). Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. *Cell* 93, 741-753.
- Wigle J.T. and Oliver G. (1999). Prox1 function is required for the development of the murine lymphatic system. *Cell* 98, 769-778.
- Wigle J.T., Harvey N., Detmar M., Lagutina I., Grosveld G., Gunn M.D., Jackson D.G. and Oliver G. (2002). An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J.* 21, 1505-1513.
- Yamazaki T., Yoshimatsu Y., Morishita Y., Miyazono K. and Watabe T. (2009). COUP-TFII regulates the functions of Prox1 in lymphatic endothelial cells through direct interaction. *Genes Cells* 14, 425-434.
- You L.R., Lin F.J., Lee C.T., DeMayo F.J., Tsai M.J. and Tsai S.Y. (2005). Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. *Nature* 435, 98-104.
- Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K. and Eichmann A. (2002). Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development* 129, 4797-4806.
- Yurugi-Kobayashi T., Itoh H., Schroeder T., Nakano A., Narazaki G., Kita F., Yanagi K., Hiraoka-Kanie M., Inoue E., Ara T., Nagasawa T., Just U., Nakao K., Nishikawa S., Yamashita J.K. (2006). Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. *Arterioscler. Thromb. Vasc. Biol.* 26, 1977-1984.
- Zhong T.P., Childs S., Leu J.P. and Fishman M.C. (2001). Gridlock signalling pathway fashions the first embryonic artery. *Nature* 414, 216-220.

Accepted October 23, 2009